
Debate Point

Dydrogesterone is effective for luteal phase support in ART cycles

Comparison of efficacy of dydrogesterone with MVP gel and VPC in fresh cycle IVF1



Dydrogesterone is a favourable drug for LPS in fresh cycle IVF women

Abbreviation: OD: Oral dydrogesterone, LPS: Luteal phase support, MVP: Micronized vaginal progesterone, VPC: Vaginal progesterone capsules

Dydrogesterone for luteal phase support in ART cycles²⁻⁷

Assisted reproductive technologies (ART) result in luteal phase deficiency which is identified by inadequate progesterone production²


Dydrogesterone has high progesterone receptor selectivity Dydrogesterone is associated with good tolerability and bioavailability (28%)

Oral dydrogesterone is the new standard for luteal phase support in fresh transfer IVF cycles

CONCLUSION

ydrogesterone treatment leads to comparatively higher pregnancy rates and lower miscarriage rates in fresh IVF cycles.

References: 1. Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95(6):1961-5. 2. Mohammed A, Woad KJ, Mann GE, Craigon J, Raine-Fenning N, Robinson RS. Evaluation of progestogen supplementation for luteal phase support in fresh in vitro fertilization cycles. Fertility and Sterility. 2019;112(3):491-502e3. 3. Panagiotis D, Caroline R, Michel DV, Shari M, AnnaLisa R, Herman T, Christophe B.The Future of Luteal Phase Support in ART and the Role of Dydrogesterone. Frontiers in Reproductive Health. 2021;2. 4. Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? FertilSteril. 2018;109(5):756-762. 5. Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reproductive depressed support in 1972-198. Some versus intravaginal micronized progesterone gel for luteal phase support in 1972-198. Hum Reproductive outcomes in IVF with oral dydrogesterone for luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020;15(11):e0241044. 7. Netter A, Mancini J, Buffat C, Agostini A, Pernin J, Courbiere B. Do early luteal serum progesterone levels predict the reproductive outcomes in IVF with oral dydrogesterone for luteal phase support: PLoS One. 2019;14(7):e0220450.



Oral route of administration (of dydrogesterone) is associated with higher tolerability than other routes in luteal phase defect^{1,2}

About 10.5% of patients report vaginal discharge or irritation with MVP

Dydrogesterone has a significantly more acceptance rate due to better tolerability compared to MVP (p<0.05)

Patient tolerability is higher when **longer treatment** required with dydrogesterone

Oral route is preferred more than vaginal route

> More costeffectiveness



Advantages of dydrogesterone in fresh cycle IVF1,3,4



Comparatively superior preanancy rates in fresh cycle IVF





Lower miscarriage



Lesser side effects

CONCLUSION

ydrogesterone is a front-line standard in fresh IVF cycles and its oral route confers higher tolerability than other routes in luteal phase defect.

- 1. Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? FertilSteril. 2018;109(5):756-762.
- 2. Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginalmicronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid BiochemMol Biol. 2005;97(5):416-20.
- Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95(6):1961-5.
- Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO, Martins WP, Nakagawa HM. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis. JBRA Assist Reprod. 2018;22(2):148-156.

Passi HealthCom

Disclaimer: The scientific content of this publication has been developed by Passi HealthCom Pvt Ltd. for educational purpose through an educational grant of Alkem Laboratories Pvt. Ltd. This publication is distributed free of cost as a service to the medical profession for educational purpose only. The content herein has been developed by content generators of Passi HealthCom Pvt Ltd. for publishing the material appearing in this publication. Readers should verify the facts of the judgements from the certified copies. Although greatest possible care has been taken in compiling, checking and developing the content to ensure that it is accurate and complete, the authors, the publisher, its servants or agents, or Alkem Laboratories Pvt. Ltd., shall not be responsible or in anyway liable for any injury or damage to any persons in view of any reliance placed on or action taken on basis of the information in this publication or any errors, omissions or inaccuracies and/or incompleteness of the information in this publication, whether arising from negligence or otherwise. The expert comments expressed in this publication are solely the views of the authors giving such expert comments. Alkem Laboratories Pvt. Ltd. neither agrees nor disagrees with the views expressed in this publication and does not constitute or imply an endorsement, sponsorship or recommendation. As the information contained herein is for educational purpose only we request you to please refer to the full prescribing information for complete details of any products.

